Collin Blakely MD Ph.D.
Hematologic Oncology, Thoracic Cancer
Clinical Instructor, Internal Medicine, UCSF School of Medicine
Join to View Full Profile
505 Parnassus AveSan Francisco, CA 94143
Phone+1 415-885-7276
Fax+1 415-353-9615
Dr. Blakely is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2009 - 2011
University of Pennsylvania Health SystemResidency, Internal Medicine, 2007 - 2009
Perelman School of Medicine at the University of PennsylvaniaClass of 2007
Certifications & Licensure
CA State Medical License 2009 - 2026
PA State Medical License 2007 - 2009
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
Clinical Trials
- Rociletinib (CO-1686) USA Expanded Access Program
- Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2017 Sep 09
- Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery Start of enrollment: 2018 Jul 31
Publications & Presentations
PubMed
- Neoadjuvant Tyrosine Kinase Inhibitors.Gavitt A Woodard, Ryan J Kramer, Collin M Blakely
Thoracic Surgery Clinics. 2026-02-01 - 22 citationsNeoadjuvant Osimertinib for Resectable-Mutated Non-Small Cell Lung Cancer.Jianxing He, Masahiro Tsuboi, Walter Weder, Ke-Neng Chen, Maximilian J Hochmair
Journal of Clinical Oncology. 2025-09-10 - 1 citationsAssociations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer.Howard J Lee Jr, John Boscardin, Louise C Walter, Alexander K Smith, Harvey J Cohen
The Oncologist. 2025-08-04
Journal Articles
- Aurora Kinase A Drives the Evolution of Resistance to Third-Generation EGFR Inhibitors in Lung CancerVictoria E Wang, Collin M Blakely, Trever G Bivona, Andrei Goga, Nature
- Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient with a MET Exon 14 Skipping MutationJulia K Rotow, Trever G Bivona, Collin M Blakely, Clinical Lung Cancer
Authored Content
- Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient with a MET Exon 14 Skipping MutationNovember 2018
Press Mentions
Damon Runyon Cancer Research Foundation Awards $4.8 Million to Rising InvestigatorsJuly 15th, 2021
Deadly Lung Cancers Are Driven by Multiple Genetic ChangesNovember 6th, 2017
Deadly Lung Cancers Are Driven by Multiple Genetic ChangesNovember 6th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
